Prescription drug costs are one of the fastest-growing and most significant components of employer healthcare spending, often accounting for 20% to 25% of total medical claims costs for employer-sponsored plans. For many employers, drug spending has been growing faster than inflation and general medical cost trends; the 2026 Milliman Medical Index measured pharmacy costs up 14.8% year over year. This makes prescription drugs a strategic priority for benefits managers and HR leaders looking to control overall healthcare expenditures while maintaining competitive offerings.
Why Prescription Drugs Are Driving Spending Growth
The surge in drug costs is driven by several interconnected factors, including the rising prevalence of specialty medications for chronic and complex conditions. Unlike traditional small-molecule drugs, specialty drugs, used to treat cancers, autoimmune diseases, hepatitis C, and rare genetic disorders, can cost tens of thousands of dollars per patient per year. Employers are also facing increased use of high-cost biologics and gene therapies, which can carry list prices of $1 million or more per treatment, with several exceeding $3 million.
Key Cost Drivers for Employers
- Specialty drugs: Although they represent only about 2% of prescriptions, specialty drugs account for nearly 50% of total drug spending for employer plans.
- Pipeline innovation: New, high-cost cell and gene therapies, as well as advanced cancer treatments, are entering the market faster than ever.
- Price inflation: Manufacturers continue to increase list prices on existing brand-name drugs year over year, even when competition exists.
- Rebate and PBM complexities: Pharmacy benefit manager (PBM) rebates and fees often obscure true net costs, making it difficult for employers to assess actual spending.
- GLP-1 agonist demand: Diabetes and weight-loss drugs are now the most commonly cited pharmacy cost driver in employer surveys.
How Employers Are Responding to Drug Cost Pressures
In response to escalating costs, employers are adopting a multipronged approach that goes beyond traditional plan design. Many are redesigning their pharmacy benefits to incentivize value and transparency, while also exploring alternative funding models and wellness-integrated strategies.
Common Strategies in Practice
- Implementing step therapy and prior authorization: These utilization management tools ensure lower-cost, clinically equivalent options are tried first before more expensive drugs are approved.
- Carving out pharmacy benefits: Some employers separate pharmacy from medical benefits to negotiate more aggressively with PBMs or to partner with independent pharmacy consultants.
- Adopting reference-based pricing: Setting maximum allowed amounts for specific drug classes, often based on a percentage of Medicare pricing.
- Using accumulator and maximizer programs: These strategies adjust how manufacturer copay assistance affects deductibles and out-of-pocket maximums, but they require careful compliance with ERISA and state insurance regulations.
- Promoting biosimilars and generics: Encouraging use of lower-cost alternatives through formulary design and member education.
The Employee Wellness Connection
Prescription drug costs affect more than the bottom line. They intersect directly with employee health outcomes and wellness program effectiveness. When employees cannot afford their medications, adherence drops, leading to worsening chronic conditions, higher emergency room use, and greater long-term medical costs. Employers that invest in comprehensive pharmacy benefits with low copays for maintenance medications often see better population health and lower total costs over time. Smart employers integrate pharmacy data into their wellness strategies, identifying gaps in medication adherence and offering targeted coaching or condition management programs.
Regulatory and Compliance Considerations
Employers must navigate a complex web of regulations when managing drug costs. The Affordable Care Act (ACA) lists prescription drugs among its essential health benefits, a standard that individual and small-group plans must meet, while ERISA imposes fiduciary duties on plan sponsors to act prudently when selecting and monitoring PBMs. The Consolidated Appropriations Act, 2021 (CAA) added specific duties: plan fiduciaries must confirm that brokers, consultants, and PBMs disclose their direct and indirect compensation, and must attest each year that no gag clause blocks access to pricing and claims data. In January 2026, the Department of Labor proposed a rule that would require PBMs and affiliated consultants to disclose their compensation to self-insured plan fiduciaries. Additionally, HIPAA privacy rules apply to pharmacy claims data, and emerging state-level transparency laws require more disclosure of drug pricing and PBM practices. Noncompliance can result in penalties and legal exposure, which is why employers should work with experienced benefits consultants and legal advisors.
GLP-1 Agonists: A New Pharmacy Cost Driver
Weight-loss and diabetes drugs have become the fastest-growing pharmacy line item for employer plans. GLP-1 agonists such as semaglutide and tirzepatide carry list prices above $1,000 per month before rebates, and Mercer reports that 77% of large employers now rank managing GLP-1 costs as very or extremely important. The cost gap is measurable. Segal's Health Plan Cost Trend Survey found prescription drug costs rose 18.3% in 2025 among plans that covered GLP-1s for obesity, compared with 10.5% for plans that limited coverage to diabetes treatment. Employers are responding with prior authorization, step therapy, lifestyle program requirements, higher copays, and, in some cases, no coverage for weight-loss use at all. Each option trades cost control against employee access, and the trade is getting sharper as oral formulations and next-generation candidates move through the pipeline.
The Bottom Line for Employers
Prescription drug costs are now a primary driver of healthcare spending that demands active management. Employers who treat drug cost management as a strategic priority, with a focus on transparency, employee health outcomes, and compliance, are better positioned to control premiums and maintain viable benefit programs. As new high-cost therapies continue to come to market, the role of prescription drugs in employer healthcare spending will only grow, making proactive strategies an essential part of long-term benefits planning.